SABS — SAB Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1833214 ·
Last close
$2.95
Market Cap
$265.76M
52W High
$5.15
52W Low
$2.44
ADV30
682,385
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -25,899,000 | -22,300,000 | 235,644,000 | 14,438,000 | 24,723,000 |
| Jun 2026 | 0 | — | -23,377,000 | -22,491,000 | 238,210,000 | 8,267,000 | 23,425,000 |
| Mar 2026 | 0 | — | -19,997,736 | -18,868,885 | 248,470,498 | 20,519,724 | 21,222,197 |
| Dec 2025 | 0 | — | -15,770,231 | -16,860,743 | 172,809,969 | 10,502,680 | 21,315,594 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-53,911,327
Investing CF
$-66,168,155
Financing CF
$105,244,315
CapEx
$-3,912,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.08
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-174,555,000
Inventory
—
Receivables
$1,504,000
ST Investments
$89,611,000
EBIT TTM
$-83,931,421
Pretax Income TTM
$-80,520,628
Interest Exp TTM
$231,499
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -48,953,363 | 13,273,683 | 172,809,969 | 21,315,594 | 151,494,375 | -44,775,111 |
| Dec 2024 | 0 | -42,910,520 | -34,105,309 | 44,195,469 | 18,225,893 | 25,969,576 | -34,292,009 |
| Dec 2023 | 0 | -38,075,320 | -42,193,786 | 83,941,253 | 26,641,812 | 57,299,441 | -25,119,405 |
| Dec 2022 | 0 | -28,917,617 | -18,740,804 | 50,904,927 | 19,846,785 | 31,058,142 | -23,459,511 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-12,775,159
OpCashFlow TTM
—
Assets (Latest)
$238,210,000
Forward EPS
$-0.95
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRXB | TRex Bio, Inc. | $274.46M | $10.00 | — |
| ALLO | Allogene Therapeutics, Inc. | $257.08M | $0.74 | — |
| OCGN | Ocugen, Inc. | $256.75M | $0.76 | — |
| EIKN | Eikon Therapeutics, Inc. | $279.06M | $5.15 | — |
| AGEN | AGENUS INC | $280.98M | $6.21 | — |
News headlines (Yahoo Finance, 1h cache)
SAB Biotherapeutics (SABS) Q3 2026 Earnings Call Transcript
2026-11-06 21:01 · Yahoo
SAB Biotherapeutics Inc (SABS) (Q3 2026) Earnings Call Highlights: FDA Fast-Track Win, Full ...
2026-11-05 23:15 · Yahoo
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
2026-11-05 12:30 · Yahoo
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
2026-10-29 12:30 · Yahoo
SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
2026-10-23 05:02 · Yahoo
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
2026-10-14 12:30 · Yahoo
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
2026-10-13 12:30 · Yahoo
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
2026-09-22 12:30 · Yahoo
SAB BIO to Participate in Upcoming Investor Conferences
2026-09-01 12:30 · Yahoo
SAB Biotherapeutics Q2 Earnings Call Highlights
2026-08-07 12:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.